VSTM
Neutral signalScored 2026-10-07 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Verastem, Inc.
- Nom
- Verastem, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $911.1M
- Employés
- 102
- PDG
- Daniel W. Paterson
- Site web
- https://www.verastem.com
- Marché
- ACRVANLBBOTCCCCCRDFFHTX
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 44 121 titres (~352 968,00 $ US)
- Insiders
- Paterson Dan
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$381,484
Avg sell (VWAP, 90d window) $7.94 vs last close $8.27 (+4.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$381,484 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-01
- Liquidity
- Thin $19,555,804/day · 20d vol
- Last synced
-
2026-10-07 21:11:04
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-01 | Calkins Daniel | Sell · S · 10b5-1 | 2,566 | $8.00 | $20,528 | Form 4 |
| 2026-10-01 | Paterson Dan | Sell · S · 10b5-1 | 44,121 | $8.00 | $352,968 | Form 4 |
| 2026-09-21 | Calkins Daniel | Sell · S · 10b5-1 | 55 | $7.70 | $424 | Form 4 |
| 2026-08-03 | Paterson Dan | Sell · S · 10b5-1 | 1,302 | $5.81 | $7,565 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-07 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
VSTM presents a mixed profile: a meaningful catalyst score (65) backed by a dual clinical readout in October, commercial launch momentum for Avmapki Fakzynja, and multiple analyst buy ratings provides a credible…
The first sentence of the analysis written for VSTM on 2026-10-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $381K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $381K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 3.09 · operating margin -550% — readings disagree
Suggested stop 7.34, nearest stored support minus 0.5 ATR(11.2% under the last close). Reward/risk to the next stored resistance is 0.40. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 82.9% | 100.0% | 0.0% | 100.0% | 100.0% | |
| Ebit Margin | -673.9% | -1258.9% | 0.0% | -2761.0% | -2982.4% | |
| Ebitda Margin | -671.6% | -1258.6% | 0.0% | -2756.4% | -2978.9% | |
| Operating Profit Margin | -550.3% | -1149.6% | 0.0% | -2809.6% | -2991.2% | |
| Pretax Profit Margin | -677.6% | -1304.5% | 0.0% | -2843.3% | -3468.1% | |
| Continuous Operations Profit Margin | -677.6% | -1306.4% | 0.0% | -2843.3% | -3468.1% | |
| Net Profit Margin | -677.6% | -1306.4% | 0.0% | -2843.3% | -3468.1% | |
| Bottom Line Profit Margin | -677.6% | -1306.4% | 0.0% | -2843.3% | -3468.1% | |
| Current Ratio | 3.091 | 3.066 | 5.447 | 4.287 | 5.688 | |
| Quick Ratio | 3.066 | 3.066 | 5.447 | 4.287 | 5.688 | |
| Solvency Ratio | -1.103 | -1.001 | -0.945 | -1.546 | -3.371 | |
| Cash Ratio | 2.837 | 2.868 | 2.953 | 3.459 | 1.143 | |
| Price To Earnings Ratio | -2.556 | -1.413 | -2.056 | -1.050 | -5.000 | |
| Price To Earnings Growth Ratio | 0.146 | 0.186 | 0.154 | 0.148 | 0.733 | |
| Forward Price To Earnings Growth Ratio | 0.146 | 0.186 | 0.154 | 0.148 | 0.733 | |
| Price To Earnings Diluted Ratio | -2.556 | -1.413 | -2.056 | -1.050 | -5.000 | |
| Price To Earnings Diluted Growth Ratio | 0.146 | 0.186 | 0.154 | 0.148 | 0.733 | |
| Price To Book Ratio | 9.355 | -6.390 | 3.129 | 1.635 | 4.083 | |
| Price To Sales Ratio | 17.308 | 18.464 | 0.000 | 29.839 | 174.151 | |
| Price To Free Cash Flow Ratio | -3.891 | -1.762 | -2.076 | -1.217 | -6.658 | |
| Price To Operating Cash Flow Ratio | -3.891 | -1.762 | -2.076 | -1.217 | -6.683 | |
| Debt To Assets Ratio | 0.312 | 0.416 | 0.278 | 0.285 | 0.029 | |
| Debt To Equity Ratio | 1.344 | -1.462 | 0.724 | 0.571 | 0.036 | |
| Debt To Capital Ratio | 0.573 | 3.162 | 0.420 | 0.364 | 0.035 | |
| Long Term Debt To Capital Ratio | 0.572 | 3.442 | 0.411 | 0.341 | 0.003 | |
| Financial Leverage Ratio | 4.309 | -3.514 | 2.610 | 2.006 | 1.241 | |
| Working Capital Turnover Ratio | 0.287 | 0.110 | 0.000 | 0.033 | 0.019 | |
| Operating Cash Flow Ratio | -1.903 | -3.383 | -3.277 | -2.939 | -2.878 | |
| Operating Cash Flow Sales Ratio | -4.448 | -10.477 | 0.000 | -24.527 | -26.060 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.004 | |
| Debt Service Coverage Ratio | -124.091 | -27.630 | -20.093 | -29.667 | -6.133 | |
| Interest Coverage Ratio | -149.498 | -25.199 | -22.248 | -34.131 | -6.158 | |
| Short Term Operating Cash Flow Coverage Ratio | -257.026 | 0.000 | 0.000 | -231.538 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1.789 | -2.480 | -2.081 | -2.353 | -16.825 | |
| Capital Expenditure Coverage Ratio | 0.000 | -3,741.821 | 0.000 | 0.000 | -272.969 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | -3,741.821 | 0.000 | 0.000 | -272.969 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.960 | -1.097 | -1.721 | -0.414 | -5.551 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 82.9% | ▼-17.1% | ▲6.3% |
| Ebit Margin | -673.9% | ▲585.0% | ▲861.3% |
| Ebitda Margin | -671.6% | ▲587.1% | ▲861.5% |
| Operating Profit Margin | -550.3% | ▲599.2% | ▲949.8% |
| Pretax Profit Margin | -677.6% | ▲626.9% | ▲981.1% |
| Continuous Operations Profit Margin | -677.6% | ▲628.8% | ▲981.5% |
| Net Profit Margin | -677.6% | ▲628.8% | ▲981.5% |
| Bottom Line Profit Margin | -677.6% | ▲628.8% | ▲981.5% |
| Current Ratio | 3.091 | ▲0.025 | ▼-1.224 |
| Quick Ratio | 3.066 | ▲0.000 | ▼-1.245 |
| Solvency Ratio | -1.103 | ▼-0.102 | ▲0.490 |
| Cash Ratio | 2.837 | ▼-0.031 | ▲0.185 |
| Price To Earnings Ratio | -2.556 | ▼-1.144 | ▼-0.141 |
| Price To Earnings Growth Ratio | 0.146 | ▼-0.040 | ▼-0.127 |
| Forward Price To Earnings Growth Ratio | 0.146 | ▼-0.040 | ▼-0.127 |
| Price To Earnings Diluted Ratio | -2.556 | ▼-1.144 | ▼-0.141 |
| Price To Earnings Diluted Growth Ratio | 0.146 | ▼-0.040 | ▼-0.127 |
| Price To Book Ratio | 9.355 | ▲15.745 | ▲6.992 |
| Price To Sales Ratio | 17.308 | ▼-1.155 | ▼-30.644 |
| Price To Free Cash Flow Ratio | -3.891 | ▼-2.129 | ▼-0.770 |
| Price To Operating Cash Flow Ratio | -3.891 | ▼-2.129 | ▼-0.765 |
| Debt To Assets Ratio | 0.312 | ▼-0.104 | ▲0.048 |
| Debt To Equity Ratio | 1.344 | ▲2.806 | ▲1.101 |
| Debt To Capital Ratio | 0.573 | ▼-2.589 | ▼-0.338 |
| Long Term Debt To Capital Ratio | 0.572 | ▼-2.870 | ▼-0.382 |
| Financial Leverage Ratio | 4.309 | ▲7.823 | ▲2.978 |
| Working Capital Turnover Ratio | 0.287 | ▲0.177 | ▲0.198 |
| Operating Cash Flow Ratio | -1.903 | ▲1.480 | ▲0.973 |
| Operating Cash Flow Sales Ratio | -4.448 | ▲6.029 | ▲8.655 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.000 | ▼-0.001 |
| Debt Service Coverage Ratio | -124.091 | ▼-96.461 | ▼-82.569 |
| Interest Coverage Ratio | -149.498 | ▼-124.300 | ▼-102.052 |
| Short Term Operating Cash Flow Coverage Ratio | -257.026 | ▼-257.026 | ▼-159.313 |
| Operating Cash Flow Coverage Ratio | -1.789 | ▲0.691 | ▲3.316 |
| Capital Expenditure Coverage Ratio | 0.000 | ▲3741.821 | ▲802.958 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | ▲3741.821 | ▲802.958 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.960 | ▼-0.863 | ▲0.188 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $535.1M | $184.6M | $179.5M | $77.5M | $357.5M | |
| Enterprise value | $406.9M | $138.1M | $143.2M | $29.6M | $339.5M | |
| EV / Sales | 13.16x | 13.81x | 0.00x | 11.40x | 165.35x | |
| EV / Op. cash flow | -2.96x | -1.32x | -1.66x | -0.47x | -6.34x | |
| EV / Free cash flow | -2.96x | -1.32x | -1.66x | -0.47x | -6.32x | |
| EV / EBITDA | -1.96x | -1.10x | -1.72x | -0.41x | -5.55x | |
| Net debt / EBITDA | 0.62x | 0.37x | 0.44x | 0.67x | 0.30x | |
| Current ratio | 3.09x | 3.07x | 5.45x | 4.29x | 5.69x | |
| Income quality | 0.66x | 0.80x | 0.99x | 0.86x | 0.75x | |
| Graham net-net | $0 | -$1 | $2 | $2 | $5 | |
| Tax burden | 100.0% | 100.1% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.5% | 103.6% | 105.0% | 103.0% | 116.3% | |
| Working capital | $151.1M | $64.0M | $117.3M | $71.2M | $87.2M | |
| Invested capital | $168.1M | $65.4M | $118.5M | $73.1M | $89.7M | |
| Return on assets | -85.0% | -128.7% | -58.4% | -77.7% | -65.5% | |
| Operating ROA | -97.8% | -91.5% | -75.2% | -71.6% | -46.7% | |
| Return on tangible assets | -91.1% | -128.7% | -58.4% | -77.7% | -65.5% | |
| Return on equity | -366.2% | 452.1% | -152.3% | -155.8% | -81.3% | |
| Return on invested capital | -97.4% | -160.6% | -74.1% | -98.0% | -67.7% | |
| Return on capital employed | -97.7% | -162.9% | -74.7% | -99.4% | -68.2% | |
| Earnings yield | -39.1% | -70.8% | -48.7% | -95.3% | -19.9% | |
| Free cash flow yield | -25.7% | -56.8% | -48.2% | -82.2% | -15.0% | |
| Capex / Op. cash flow | 0.0% | -0.0% | 0.0% | 0.0% | -0.4% | |
| Capex / Depreciation | 0.0% | 107.7% | 0.0% | 0.0% | 272.2% | |
| Capex / Sales | 0.0% | 0.3% | 0.0% | 0.0% | 9.5% | |
| SG&A / Sales | 262.5% | 436.2% | 0.0% | 962.1% | 1174.6% | |
| R&D / Sales | 370.7% | 813.3% | 0.0% | 1947.5% | 1916.6% | |
| Stock comp / Sales | 30.4% | 73.4% | 0.0% | 232.9% | 375.6% | |
| Intangibles / Total assets | 6.7% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 104d | 7d | 0d | 4d | 92d | |
| Days payables outstanding | 858d | 0d | 0d | 0d | 0d | |
| Operating cycle | 230d | 7d | 0d | 4d | 92d | |
| Cash conversion cycle | -627d | 7d | 0d | 4d | 92d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-06 Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch Verastem is performing commercially with Avmapki Fakzynja Co-pack and advancing in the clinic with its KRAS G12D inhibitor, VS-7375, in multiple cancers. Q2 ''26 net product revenues reached $25.1M in just the fourth quarter of the launch of Co-pack. An October readout from the TARGET-D 101 trial of VS-7375 in solid tumors represents a significant near-term clinical catalyst.
- 2026-10-05 Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to 24 new employees and stock options to purchase 50,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee''s acceptance of employment with Vera.
- 2026-10-05 Verastem (NASDAQ:VSTM) Given Buy Rating at BTIG Research Verastem (NASDAQ: VSTM - Get Free Report)''s stock had its "buy" rating reiterated by stock analysts at BTIG Research in a research note issued to investors on Monday, Benzinga reports. They currently have a $18.00 target price on the biopharmaceutical company''s stock. BTIG Research''s price objective would indicate a potential upside of 133.77% from the company''s
- 2026-10-05 HC Wainwright Reaffirms “Buy” Rating for Verastem (NASDAQ:VSTM) Verastem (NASDAQ: VSTM - Get Free Report)''s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a report released on Monday, MarketBeat Ratings reports. They presently have a $18.00 target price on the biopharmaceutical company''s stock. HC Wainwright''s target price would suggest a potential upside of 133.77% from the company''s current price.
- 2026-10-02 Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026 BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--New RAMP 201 Molecular Profiling and External Control Arm Analyses Supports Outcomes for Avutometinib Plus Defactinib in Recurrent LGSOC.
- 2026-09-29 Head to Head Survey: Verastem (NASDAQ:VSTM) & Sangamo Therapeutics (NASDAQ:SGMO) Verastem (NASDAQ: VSTM - Get Free Report) and Sangamo Therapeutics (NASDAQ: SGMO - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability. Analyst Recommendations This is a breakdown of current
- 2026-09-28 Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.
- 2026-09-24 Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem to present late-breaking oral presentation of RAMP 201 LGSOC molecular profiling and tumor biomarker analysis at IGCS 2026.
- 2026-09-24 Verastem (NASDAQ:VSTM) Shares Up 7.1% – Time to Buy? Shares of Verastem, Inc. (NASDAQ: VSTM - Get Free Report) rose 7.1% during trading on Tuesday. The company traded as high as $8.31 and last traded at $8.56. Approximately 218,604 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 2,235,085 shares. The stock had previously closed at $7.99.
- 2026-09-21 Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright Verastem NASDAQ: VSTM executives outlined the company''s commercial and clinical priorities at an H.C. Wainwright event, highlighting the launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated low-grade serous ovarian cancer and the advancement of its KRAS G12D inhibitor, VS-7375, across pancreatic, lung and colorectal cancers.